Kaplan–Meier analysis showed a significantly longer recurrence-free and overall survival in patients with high p-ERK1/2 expression (>20% tumour cells) as determined by immunohistochemistry and in cases with strong p-ERK1 expression as measured by Western blots and densitometry (Figure 2). This evidence concerns the gene MAPK3 and neoplasm.